The genetics and neuropathology of frontotemporal lobar degeneration
- PMID: 22890575
- PMCID: PMC3422616
- DOI: 10.1007/s00401-012-1029-x
The genetics and neuropathology of frontotemporal lobar degeneration
Abstract
Frontotemporal lobar degeneration (FTLD) is a heterogeneous group of disorders characterized by disturbances of behavior and personality and different types of language impairment with or without concomitant features of motor neuron disease or parkinsonism. FTLD is characterized by atrophy of the frontal and anterior temporal brain lobes. Detailed neuropathological studies have elicited proteinopathies defined by inclusions of hyperphosphorylated microtubule-associated protein tau, TAR DNA-binding protein TDP-43, fused-in-sarcoma or yet unidentified proteins in affected brain regions. Rather than the type of proteinopathy, the site of neurodegeneration correlates relatively well with the clinical presentation of FTLD. Molecular genetic studies identified five disease genes, of which the gene encoding the tau protein (MAPT), the growth factor precursor gene granulin (GRN), and C9orf72 with unknown function are most frequently mutated. Rare mutations were also identified in the genes encoding valosin-containing protein (VCP) and charged multivesicular body protein 2B (CHMP2B). These genes are good markers to distinguish underlying neuropathological phenotypes. Due to the complex landscape of FTLD diseases, combined characterization of clinical, imaging, biological and genetic biomarkers is essential to establish a detailed diagnosis. Although major progress has been made in FTLD research in recent years, further studies are needed to completely map out and correlate the clinical, pathological and genetic entities, and to understand the underlying disease mechanisms. In this review, we summarize the current state of the rapidly progressing field of genetic, neuropathological and clinical research of this intriguing condition.
Figures
Similar articles
-
[The molecular pathology of frontotemporal lobar degeneration].Seishin Shinkeigaku Zasshi. 2010;112(4):313-24. Seishin Shinkeigaku Zasshi. 2010. PMID: 20496755 Review. Japanese.
-
Clinic, neuropathology and molecular genetics of frontotemporal dementia: a mini-review.Transl Neurodegener. 2013 Apr 19;2(1):8. doi: 10.1186/2047-9158-2-8. Transl Neurodegener. 2013. PMID: 23597030 Free PMC article.
-
Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.Acta Neuropathol. 2007 Jul;114(1):5-22. doi: 10.1007/s00401-007-0237-2. Epub 2007 Jun 20. Acta Neuropathol. 2007. PMID: 17579875 Free PMC article.
-
Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype.Brain Pathol. 2017 Nov;27(6):723-736. doi: 10.1111/bpa.12486. Epub 2017 Mar 2. Brain Pathol. 2017. PMID: 28100023 Free PMC article. Review.
-
Reduced Tau protein expression is associated with frontotemporal degeneration with progranulin mutation.Acta Neuropathol Commun. 2016 Jul 19;4(1):74. doi: 10.1186/s40478-016-0345-0. Acta Neuropathol Commun. 2016. PMID: 27435172 Free PMC article.
Cited by
-
The Lysosomal Trafficking Transmembrane Protein 106B Is Linked to Cell Death.J Biol Chem. 2016 Oct 7;291(41):21448-21460. doi: 10.1074/jbc.M116.737171. Epub 2016 Aug 25. J Biol Chem. 2016. PMID: 27563066 Free PMC article.
-
C9orf72 immunohistochemistry in Alzheimer's disease.Alzheimers Res Ther. 2012 Sep 26;4(5):37. doi: 10.1186/alzrt140. eCollection 2012. Alzheimers Res Ther. 2012. PMID: 23014271 Free PMC article.
-
Repeat-associated non-AUG (RAN) translation mechanisms are running into focus for GGGGCC-repeat associated ALS/FTD.Prog Neurobiol. 2019 Dec;183:101697. doi: 10.1016/j.pneurobio.2019.101697. Epub 2019 Sep 21. Prog Neurobiol. 2019. PMID: 31550516 Free PMC article. Review.
-
Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.J Alzheimers Dis. 2018;62(3):1199-1209. doi: 10.3233/JAD-170680. J Alzheimers Dis. 2018. PMID: 29562530 Free PMC article. Review.
-
N-Acetyl-Cysteine: Modulating the Cysteine Redox Proteome in Neurodegenerative Diseases.Antioxidants (Basel). 2022 Feb 18;11(2):416. doi: 10.3390/antiox11020416. Antioxidants (Basel). 2022. PMID: 35204298 Free PMC article. Review.
References
-
- Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, Yu X, Wuertzer CA, Hou H, Chiba S, Yamanouchi K, Leissring M, Petrucelli L, Nishihara M, Hutton ML, McGowan E, Dickson DW, Lewis J. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol. 2010;177(1):311–324. doi: 10.2353/ajpath.2010.090915. - DOI - PMC - PubMed
-
- Al-Sarraj S, King A, Troakes C, Smith B, Maekawa S, Bodi I, Rogelj B, Al-Chalabi A, Hortobágyi T, Shaw CE. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72 linked FTLD and MND/ALS. Acta Neuropathol. 2011;122(6):691–702. doi: 10.1007/s00401-011-0911-2. - DOI - PubMed
-
- Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602–611. doi: 10.1016/j.bbrc.2006.10.093. - DOI - PubMed
-
- Arighi A, Fumagalli GG, Jacini F, Fenoglio C, Ghezzi L, Pietroboni AM, De Riz M, Serpente M, Ridolfi E, Bonsi R, Bresolin N, Scarpini E, Galimberti D (2012) Early onset behavioral variant frontotemporal dementia due to the C9ORF72 hexanucleotide repeat expansion: psychiatric clinical presentations. J Alzheimers Dis (Epub ahead of print) - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous